Literature DB >> 2328195

Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration.

C J Gavey1, J T Smith, C U Nwokolo, R E Pounder.   

Abstract

1. We studied the effects of acute oral dosing with clofibrate (500 mg four times daily) on 24 h intragastric acidity and plasma gastrin concentration in 12 healthy female subjects. 2. The 24 h integrated intragastric acidity rose from 429 mmol l-1 h (95% CI 296-479) before dosing to 527 mmol l-1 h (95% CI 385-664) on the day of dosing (+23%; P = 0.041), but no change was observed in the 24 h integrated plasma gastrin concentration: 420 pmol l-1 h (95% CI 282-499) before and 389 pmol l-1 h (95% CI 249-489) during dosing (P = 0.182). 3. We conclude that clofibrate has no acute antisecretory effect on the human stomach, and that human gastrin-induced enterochromaffin-like cell proliferation is unlikely with this drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328195      PMCID: PMC1380118          DOI: 10.1111/j.1365-2125.1990.tb03666.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Clofibrate: antisecretory-antiulcer activity in the rat.

Authors:  W Lippmann; K Seethaler
Journal:  J Pharm Pharmacol       Date:  1976-02       Impact factor: 3.765

2.  Effect of acid inhibition on gastric endocrine cells.

Authors:  R Arnold; H Koop; H Schwarting; K Tuch; B Willemer
Journal:  Scand J Gastroenterol Suppl       Date:  1986

3.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

Authors: 
Journal:  Br Heart J       Date:  1978-10

4.  Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.

Authors:  H Larsson; E Carlsson; H Mattsson; L Lundell; F Sundler; G Sundell; B Wallmark; T Watanabe; R Håkanson
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

Review 5.  Achlorhydria: hypergastrinaemia: carcinoids--a flawed hypothesis?

Authors:  J Penston; K G Wormsley
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

6.  Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset.

Authors:  C T Eason; A J Spencer; A Pattison; D D Howells; D C Henry; F W Bonner
Journal:  Toxicol Appl Pharmacol       Date:  1988-09-15       Impact factor: 4.219

7.  The effect of ciprofibrate on gastric secretion in the rat.

Authors:  C T Eason; A Pattison; D D Howells; F W Bonner
Journal:  J Pharm Pharmacol       Date:  1988-07       Impact factor: 3.765

8.  Gastric neuroendocrine cell hyperplasia after treatment with the long-acting, potent H2-receptor antagonist SK&F 93479.

Authors:  J H Harleman; G R Betton; C Dormer; M McCrossan
Journal:  Scand J Gastroenterol       Date:  1987-06       Impact factor: 2.423

9.  Alterations in gastric mucosal morphology induced by long-term treatment with omeprazole in rats.

Authors:  H Blom
Journal:  Digestion       Date:  1986       Impact factor: 3.216

10.  Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug.

Authors:  D J Svoboda; D L Azarnoff
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

View more
  1 in total

Review 1.  Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis.

Authors:  J W Freston; K Borch; S J Brand; E Carlsson; W Creutzfeldt; R Håkanson; L Olbe; E Solcia; J H Walsh; M M Wolfe
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.